PCOS (now also known as PMOS — Polyendocrine Metabolic Ovarian Syndrome) Is Now PMOS: What It Means for Your Health

Category: Women's Health and Metabolic Conditions

PCOS (now also known as PMOS — Polyendocrine Metabolic Ovarian Syndrome) Has a New Name — and It Changes Everything About How We Treat It

One of the most significant renamings in women's health in decades has just been confirmed. As of May 2026, polycystic ovary syndrome (now also known as PMOS — Polyendocrine Metabolic Ovarian Syndrome) — better known as PCOS (now also known as PMOS — Polyendocrine Metabolic Ovarian Syndrome) — is now officially called polyendocrine metabolic ovarian syndrome, or PMOS.

The change was published in The Lancet following a global consensus process led by Monash University, involving 56 international organisations and more than 14,000 patients and health professionals worldwide.

This is not a cosmetic rebrand. It is a correction — one that has been a long time coming, and one that has real implications for how this condition is diagnosed, treated, and understood by the women living with it.

Why the Old Name Was Doing Real Harm

The term "polycystic ovary syndrome (now also known as PMOS — Polyendocrine Metabolic Ovarian Syndrome)" was always a clinical misnomer. It implied the condition was defined by cysts on the ovaries — but pathological ovarian cysts are not actually a diagnostic requirement. The name focused attention on one organ, narrowed clinical thinking to reproductive health, and left the broader hormonal and metabolic picture largely invisible.

The consequences were measurable. PCOS (now also known as PMOS — Polyendocrine Metabolic Ovarian Syndrome) affects approximately one in eight women — more than 170 million people globally — yet research consistently shows that up to 70 per cent of those affected remain undiagnosed. A misleading name contributed to that gap. When patients and clinicians alike associate a condition with one visible feature, everything else tends to get missed.

What the New Name Actually Means

PMOS — polyendocrine metabolic ovarian syndrome — is built from three descriptors, each chosen deliberately:

Polyendocrine: the condition involves multiple hormone systems, not a single hormonal pathway
Metabolic: it fundamentally affects how the body regulates insulin, glucose, and energy
Ovarian: the ovaries remain involved, but as one component of a systemic condition

That middle word — metabolic — is the most important shift. It brings insulin resistance, cardiovascular risk, and metabolic dysfunction into the core definition of the condition, where they have always belonged clinically but were rarely centred in practice.

The Metabolic Reality Most Clinicians Already Know

For clinicians working in weight and metabolic health, the new name reflects what the evidence has shown for years.

Insulin resistance is present in approximately 85 per cent of people with PMOS. Critically, this includes around 75 per cent of women in a healthy weight range who have the condition — a finding that directly challenges the persistent misconception that PMOS is primarily a consequence of excess weight. It is not. It is a hormonal and metabolic condition that exists across the full weight spectrum.

The downstream risks are significant. PMOS is associated with substantially increased risk of:

Type 2 diabetes
Hypertension
Dyslipidaemia
Non-alcoholic fatty liver disease
Adverse cardiovascular outcomes

The 2023 international evidence-based PCOS (now also known as PMOS — Polyendocrine Metabolic Ovarian Syndrome) guidelines — developed with Monash University involvement — identified these metabolic risks as central to long-term management, not secondary concerns.

Carrying excess weight, particularly central adiposity, can amplify hormonal dysregulation and worsen insulin resistance in PMOS. But the relationship runs both ways: the condition itself makes weight management genuinely harder through its effects on insulin signalling, appetite regulation, and energy metabolism. This is not a failure of willpower. It is physiology.

What This Means for Weight Management in PMOS

If you have PMOS and weight has been part of your experience, the name change quietly validates something many women have known for a long time: the difficulty was never simply about effort, and the condition was never only about your ovaries.

Because PMOS is metabolic at its core, addressing metabolic health — including weight where clinically relevant — can be a meaningful part of comprehensive management. The evidence supports:

Lifestyle interventions as a first-line approach
Modest weight loss of five to ten per cent, which has been shown to improve hormonal markers, menstrual regularity, insulin sensitivity, and quality of life
Pharmacological options, where lifestyle change alone is insufficient, tailored to the individual in line with clinical guidelines

What that looks like in practice varies considerably from person to person. PMOS presents differently across different women — in symptom profile, severity, weight, and metabolic risk. That is precisely why a one-size-fits-all approach is inadequate, and why care needs to involve a qualified clinician who looks at your full clinical picture.

Practical Implications — What Changes and What Does Not

For most women, day-to-day life does not change overnight. A managed three-year transition period means both "PCOS (now also known as PMOS — Polyendocrine Metabolic Ovarian Syndrome)" and "PMOS" will appear in clinical settings concurrently. International guidelines — next scheduled for update in 2028 — will integrate the new terminology progressively.

If your medical records, referrals, or past results say PCOS (now also known as PMOS — Polyendocrine Metabolic Ovarian Syndrome), that is completely valid. It is the same condition, now described with greater accuracy. There is nothing you need to do differently as a result of the rename itself — but if the new framing prompts you to revisit your metabolic health with a clinician, that conversation is worth having.

How Downscale Health Approaches PMOS

At Downscale Health, we have always approached this condition as what it is: a whole-person, metabolic, and hormonal condition that deserves more than a reproductive health checklist. The new name reflects the clinical framework we already apply.

Our Nurse Practitioners — AHPRA-registered and SCOPE-certified — provide telehealth consultations across every state and territory in Australia, with a focus on evidence-based, sustainable weight and metabolic health support. There are no fad diets, no judgement, and no discharge when you reach a goal. Ongoing maintenance is built into the model because we understand that managing a metabolic condition is not a short-term project.

We see the person — the full hormonal, metabolic, and lived experience — not just a number on a scale or a single line on a referral.

The Bottom Line

PCOS (now also known as PMOS — Polyendocrine Metabolic Ovarian Syndrome) becoming PMOS is more than a wording update. It is a long-overdue correction that reframes a condition affecting one in eight Australian women as the systemic, hormonal, and metabolic condition it has always been. For anyone navigating weight and metabolic health alongside PMOS, that recognition matters — clinically and personally.

If you have PMOS (or PCOS (now also known as PMOS — Polyendocrine Metabolic Ovarian Syndrome), as it may still appear on your records) and you would like evidence-based, judgement-free support for your weight and metabolic health, our team at Downscale Health is here to help.

Book a telehealth consultation today — available anywhere in Australia.